Use of the medication levothyroxine, commonly prescribed for hypothyroidism, was associated with greater long-term loss of total body bone mass in seniors, according to new DEXA research to be presented at the Radiological Society of North America (RSNA) conference.
It has been estimated that 23 million Americans take daily levothyroxine, which is indicated for hypothyroidism, but new research to be presented at the Radiological Society of North America (RSNA) conference shows the medication can lead to higher losses of bone mass and density over time.
For the study, researchers compared dual X-ray absorptiometry (DEXA) scan data for 81 patients using levothyroxine and 364 control patients. The total cohort had a median age of 73 and a 2.35 thyrotropin (TSH) level at the initial visit, according to the study.1
Noting a median 6.3-year follow-up, the researchers found that patients in the levothyroxine cohort had greater longitudinal loss of total body bone mass (beta coefficient: -6.53) and density (beta coefficient: -0.0014).1
“Our study suggests that even when following current guidelines, levothyroxine use appears to be associated with greater bone loss in older adults,” noted Shadpour Demehri, M.D., a co-senior author of the study and a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science.
(Editor's note: For more content from the Radiological Society of North America (RSNA) conference, click here.)
The association between levothyroxine and longitudinal loss of total body bone mass was stronger with higher use of the medication. The researchers noted beta coefficients of -12 and -8.23 for total body bone mass loss at the second and third tertiles, respectively, of the mean average serum-free thyroxine (FT4) level.1
“The more pronounced effects at higher levels of FT4 suggest that LT4 use may be associated with a relative excess of thyroid hormone in some older adults on therapy, even with TSH levels within the reference range,” noted lead study author Elena Ghotbi, M.D., and colleagues.
Reference
1. Ghotbi E, Ibad H, Xue Q, Mammen J, Demehri S. Levothyroxine use and bone loss in euthyroid older adults: a longitudinal analysis from Baltimore longitudinal study of aging. Poster to be presented at the Radiological Society of North America (RSNA) 2024 110th Scientific Assembly and Annual Meeting Dec. 1-5, 2024. Available at: https://www.rsna.org/annual-meeting .
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.